AmyPore
Entity

  • AmyPore

    Created in 2018
  • BETA

    To investigate (B)
    Some signals may appear as inconsistent with a regular activity

  • Social networks

    699

  • Activities

    biotech deeptech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    51 Bd Élie Corradi, 13240 Septèmes-les-Vallons, France

    Septèmes-les-Vallons

    France

  • Employees

    Scale: 1 employee

    Estimated: 2

  • SIREN

    839945508

  • Engaged corporates

    1
    1 0

  • Added in Motherbase

    1 year, 6 months ago
Description
  • Value proposition

    New target, new paradigm, new strategy that address the root cause of Alzheimer, Parkinson, and other proteinopathies

    AmyPore is a biotechnology company based around the leading science of Pr. Nouara Yahi (University of Aix-Marseillle) and Pr. Jacques Fantini (University of Aix-Marseille and Institut Universitaire de France). Their expertise in molecular neurosciences has led to the discovery of AmyP53, a first-in-class patented nontoxic molecule which tackles a common mechanism of neurotoxicity shared by Alzheimer and Parkinson diseases. The company applies its pioneering computational discovery platform coupled with high performance lipid-protein and protein-protein binding technology and ultrasensitive Ca2+ amyloid pore reporting assay to identify and neutralize novel targets that control pathologic protein misfolding. Created in 2018, AmyPore owns exclusive patent rights for the therapeutic use of AmyP53, including the development of a nasal spray for treating patients with Alzheimer or Parkinson diseases. Beyond AmyP53, AmyPore is developing a pipeline of therapeutic peptides able to prevent the formation of oligomers implicated in the development and progression of degenerative proteinopathies, including amyotrophic lateral sclerosis (ALS) and type 2 diabetes.

    molecular dynamics simulations, drug design, biological membranes, lipid rafts, gangliosides, cholesterol, calcium imaging, lipid-protein interactions, molecular neurosciences, neurodegenerative diseases, type 2 diabetes, amyloid pores, and amyloid oligomers

  • Original language

    New target, new paradigm, new strategy that address the root cause of Alzheimer, Parkinson, and other proteinopathies

    AmyPore is a biotechnology company based around the leading science of Pr. Nouara Yahi (University of Aix-Marseillle) and Pr. Jacques Fantini (University of Aix-Marseille and Institut Universitaire de France). Their expertise in molecular neurosciences has led to the discovery of AmyP53, a first-in-class patented nontoxic molecule which tackles a common mechanism of neurotoxicity shared by Alzheimer and Parkinson diseases. The company applies its pioneering computational discovery platform coupled with high performance lipid-protein and protein-protein binding technology and ultrasensitive Ca2+ amyloid pore reporting assay to identify and neutralize novel targets that control pathologic protein misfolding. Created in 2018, AmyPore owns exclusive patent rights for the therapeutic use of AmyP53, including the development of a nasal spray for treating patients with Alzheimer or Parkinson diseases. Beyond AmyP53, AmyPore is developing a pipeline of therapeutic peptides able to prevent the formation of oligomers implicated in the development and progression of degenerative proteinopathies, including amyotrophic lateral sclerosis (ALS) and type 2 diabetes.

  • Accueil - Amypore

    AmyPore est une société de Biotechnologie qui conçoit et développe des peptides thérapeutiques dans le but de mettre au point des traitements pour les

    • https://www.amypore.com/
Corporate interactions BETA
Corporate TypeTweets Articles
La French Tech Aix-Marseille Région Sud
La French Tech Aix-Marseille Région Sud
French Tech, Software Development
La French Tech Aix-Marseille Région Sud
French Tech, Software Development 		Other

7 Sep 2024


Similar entities
Last news
Show all articles
Social network dynamics